Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers
Marina Cavazzana, MD, PhD

Marina Cavazzana, MD

Researcher
Head
Department of Biotherapy
Hôpital Necker
149 Rue de Sèvres
Paris, France

Marina Cavazzana is a pediatrician, Professor of Haematology since 2000, Head of the Biotherapy Department at Hospital Necker, University Paris Descartes. She is the Director of the Inserm / Assistance Publique – Hôpitaux de Paris GHU Ouest Biotherapy Clinical Investigation Center and leads a research Laboratory at Imagine Institute. She studied medicine in Padua, Italy and received Doctorate of Medicine in 1983, her certification in Paediatrics in 1987 and a PhD in Life Sciences in 1993 (University Paris VII).

Dr. Marina Cavazzana has dedicated her time and research in investigating innovative protocol with a particular intervention gene therapy, focusing on sickle cell disease.

Her main research and clinical interests are development of the immune system, genetic diseases of the haematopoietic system and cell and gene therapy. Her group studies the means to improve the clinical results of hematopoietic stem cell transplantation, crossing HLA-barriers, and the differentiation of mouse and human stem cells towards lymphocyte lineages. She has initiated several clinical trials based on the use of ex vivo gene modified cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging.

She is the author or co-author of one patent and of more than 270 publications in peer-reviewed journals.

 

Representative Publications:

Gene Therapy in a Patient with Sickle Cell Disease

Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks

Arterio-venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel

view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close